Aurobindo Pharma Ltd. NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

Download real time

1094.40 -14.80 (-1.33%)

31.26% Fall from 52W High

828.2K

NSE+BSE Volume

NSE 12 Sep, 2025 3:31 PM (IST)

Aurobindo Pharma Ltd. share price target

Aurobindo Pharma Ltd. has an average share price target of 1403.50. The consensus estimate represents an upside of 28.24% from the last price of 1094.40. View 17 reports from 10 analysts offering long-term price targets for Aurobindo Pharma Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	12 Sep 2025	Aurobindo Pharma	Consensus Share Price Target	1094.40	1293.39	-	18.18	buy	pdf Detailed Estimates
	13 Feb 2024	Aurobindo Pharma	Prabhudas Lilladhar Target	1094.40	1120.00	1026.40 (6.63%)	Target met	Accumulate	pdf post cache		Broker Report AUROBINDO PHARMA Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2024	Aurobindo Pharma	Axis Direct Target	1094.40	1160.00	1026.40 (6.63%)	Target met	Buy	pdf post cache		Broker Report Result Update:Aurobindo Pharma Axis Direct ABRP has a number of levers to grow its topline: 1) Generic injectibles, Eugia (USD$520 Mn sales) may grow by low double-digit growth based on value-added approval. Recommendation: BUY pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2024	Aurobindo Pharma	BOB Capital Markets Ltd. Target	1094.40	1100.00	1026.40 (6.63%)	Target met	Hold	pdf post cache		Broker Report Aurobindo Pharma (HOLD): Strong margin uptick BOB Capital Markets Ltd. Q3 EBITDA/PAT surged 68%/90% YoY led by growth in US/EM revenue and ~700bps jump in operating margin pdf Copy Link Share on Share on Share on Share on Alert
	17 Nov 2023	Aurobindo Pharma	Geojit BNP Paribas Target	1094.40	1037.00	1007.35 (8.64%)	Target met	Hold	pdf post cache		Broker Report AUROBINDO PHARMA LTD Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	13 Nov 2023	Aurobindo Pharma	Axis Direct Target	1094.40	1080.00	979.35 (11.75%)	Target met	Buy	pdf post cache		Broker Report Result Update:Aurobindo Pharma Axis Direct ABRP has several growth levers in place. These are 1) Generic injectibles, Eugia ($520 Mn sales) that could grow by low double-digit growth based on value-added approval, 2) The launch of Trastzumab biosimilars in 2FY24E pdf Copy Link Share on Share on Share on Share on Alert
	11 Nov 2023	Aurobindo Pharma	Prabhudas Lilladhar Target	1094.40	1065.00	979.70 (11.71%)	Target met	Accumulate	pdf post cache		Broker Report AUROBINDO PHARMA Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	23 Aug 2023	Aurobindo Pharma	Geojit BNP Paribas Reco Target	1094.40	915.00	838.85 (30.46%)	Target met	Hold	pdf post cache		Broker Report AUROBINDO PHARMA LTD Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	18 Aug 2023	Aurobindo Pharma	Axis Direct Target	1094.40	1000.00	857.80 (27.58%)	Target met	Buy	pdf post cache		Broker Report Result Update:Aurobindo Pharma Axis Direct Company Outlook & Guidance: ABRP has several growth levers in place. These are 1) Generic injectibles, Eugia ( Euro 411 Mn sales) that could grow by low double-digit growth based on value-added approval. pdf Copy Link Share on Share on Share on Share on Alert
	15 Aug 2023	Aurobindo Pharma	ICICI Securities Limited Target	1094.40	920.00	871.65 (25.55%)	Target met	Accumulate	pdf post cache		Broker Report Margin restoration underway ICICI Securities Limited Aurobindo’s Q1 performance was driven largely by traction in regulated markets. Lower export incentives exerted a 50bps impact on EBITDA margin, which otherwise at 16.8% would have been better than expected. US sales crossed a milestone of USD 400mn after a gap of two years. pdf Copy Link Share on Share on Share on Share on Alert
	15 Aug 2023	Aurobindo Pharma	BOB Capital Markets Ltd. Reco Target	1094.40	880.00	871.65 (25.55%)	Target met	Hold	pdf post cache		Broker Report Aurobindo Pharma (HOLD): Broad-based growth; lower to HOLD post rally BOB Capital Markets Ltd. Q1 revenue/EBITDA beat consensus by 4%/9% with adj. PAT (ex-one-off charge) running 15% ahead pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners